Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer: A meta‐analysis of randomized controlled trials

BACKGROUND: The addition of immune checkpoint inhibitors (ICIs) to chemotherapy is the new standard of care in the first‐line treatment of small cell lung cancer (SCLC). However, although the concomitant use of immunotherapy and chemotherapy can increase the antitumor efficacy, it can also increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo, Vito, Rizzo, Alessandro, Catino, Annamaria, Montrone, Michele, Galetta, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101844/
https://www.ncbi.nlm.nih.gov/pubmed/36869579
http://dx.doi.org/10.1111/1759-7714.14842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101844/
https://www.ncbi.nlm.nih.gov/pubmed/36869579
http://dx.doi.org/10.1111/1759-7714.14842

Ejemplares similares